Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer  

作　　者：Zhong-Hui Li Yin-Jie Ma Zong-Hang Jia Yue-Yan Weng Ping Zhang Shi-Jie Zhu Fang Wang 

机构地区：[1]Department of Oncology,Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China [2]Department of Oncology,Shandong University of Traditional Chinese Medicine,Jinan 250022,Shandong Province,China [3]Department of Acupuncture and Moxibustion,Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China [4]Department of Pathology,Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China

出　　处：《World Journal of Clinical Cases》2022年第27期9703-9713,共11页世界临床病例杂志

摘　　要：BACKGROUND Gemcitabine plus nab-paclitaxel(GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer,and many studies will add a novel targeted agent to this regimen for improving patient survival rate.However,the clinical effectiveness of GA is the most controversial issue.AIM To compare the efficacy and safety of GA regimen with a targeted agent and GA regimen.METHODS Up to 1 December 2021,the eligible randomized controlled trials(RCTs) relating to GA and GA with a targeted agent were searched on Pub Med,EMBASE and Cochrane Library for eligible data.We screened out appropriate studies for overall survival(OS),progression-free survival(PFS),objective response rate(ORR),and toxicity,which had been pooled and finally analyzed by using Stata version 15.1.In addition,we use Reference Citation Analysis(https://www.referencecitationanalysis.com/) to collect the latest related literature to improve the latest cutting-edge research results.RESULTS Seven RCTs involving 1544 patients(848 men and 696 women) were included.There were no significant differences between GA with a targeted agent and GA in PFS [hazard ratio(HR):1.18 95% confidence interval(CI):0.91-1.53],OS(HR:1.12 95%CI:0.99-1.27),and ORR(HR:0.96 95%CI:0.71-1.29).There was no notable difference in the two groups in grade 3/4 toxicity(fatigue,anemia,vomiting and neutropenia),whereas the incidence of grade 3/4 diarrhea considerably increased in GA with a targeted drug.CONCLUSION Adding a novel targeted agent to the GA regimen did not improve survival rate of patients with metastatic pancreatic cancer.

关 键 词：Metastatic pancreatic cancer GEMCITABINE NAB-PACLITAXEL Novel targeted agent SURVIVAL 

分 类 号：R735.9[医药卫生—肿瘤]